• 1
    Micozzi A,Venditti M,Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000; 31: 705711.
  • 2
    Khardori N,Elting L,Wong E,Schable B,Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990; 12: 9971003.
  • 3
    Denton M,Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998; 11: 5780.
  • 4
    Spangler SK,Visalli MA,Jacobs MR,Appelbaum PC. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother. 1996; 40: 772775.
  • 5
    Vartivarian SE,Papadakis KA,Palacios JA,Manning JTJr,Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med. 1994; 121: 969973.
  • 6
    Vartivarian SE,Papadakis KA,Anaissie EJ. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med. 1996; 156: 433435.
  • 7
    Papadakis KA,Vartivarian SE,Vassilaki ME,Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg. 1997; 87: 106108.
  • 8
    Sanyal SC,Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999; 11: 2833.
  • 9
    Van Couwenberghe CJ,Farver TB,Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol. 1997; 18: 316321.
  • 10
    Gopalakrishnan R,Hawley HB,Czachor JS,Markert RJ,Bernstein JM. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals. A study of 143 patients. Heart Lung. 1999; 28: 134141.
  • 11
    Carroll KC,Cohen S,Nelson R, et al. Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 1998; 32: 229235.
  • 12
    Smit WJ,Boquest AL,Geddes JE,Tosolini FA. The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology. 1994; 26: 321324.
  • 13
    Vartivarian S,Anaissie E,Bodey G,Sprigg H,Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother. 1994; 38: 624627.
  • 14
    Garrison MW,Anderson DE,Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother. 1996; 40: 28592864.
  • 15
    Fass RJ,Barnishan J,Solomon MC,Ayers LW. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996; 40: 14121418.
  • 16
    Penzak SR,Abate BJ. Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy. 1997; 17: 293301.
  • 17
    Muder RR,Harris AP,Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996; 22: 508512.
  • 18
    Saino Y,Kobayashi F,Inoue M,Mitsuhashi S. Purification and properties of inducible penicillin b-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother. 1982; 22: 564570.
  • 19
    Saino Y,Inoue M,Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother. 1984; 25: 362365.
  • 20
    Wishart MW,Riley TV. Infection with Pseudomonas maltophilia: hospital outbreak due to contaminated disinfectant. Med J Aust. 1976; 2: 710712.
  • 21
    Marshall WF,Keating MR,Anhalt JP,Steckelberg JM. Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin Proc. 1989; 64: 10971104.
  • 22
    Gales AC,Jones RN,Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001; 15;32 suppl 2( ): S104113.
  • 23
    Garner JS,Jarvis WR,Emori TG,Horan TC,Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16: 128140.
  • 24
    Harris AD,Karchmer TB,Carmeli Y,Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32: 10551061.
  • 25
    Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st century approach. Clin Infect Dis. 2002; 34: 15641567.
  • 26
    Pradhananga SL,Rowling PJ,Simpson IN,Payne DJ. Sensitivity of L-2 type beta-lactamases from Stenotrophomonas maltophilia to serine active site beta-lactamase inhibitors [letter]. J Antimicrob Chemother. 1996; 37: 394396.
  • 27
    Crowder MW,Walsh TR,Banovic L,Pettit M,Spencer J. Overexpression, purification, and characterization of the cloned metallo-betalactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1998; 42: 921926.
  • 28
    Zhang L,Xian-Zhi L,Poole K. Multiple antibiotic resistance in Stenotrophomonas: involvement of a multidrug efflux system Antimicrob Agents Chemother. 2000; 44: 287293.
  • 29
    Elting LS,Khardori N,Bodey GP,Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol. 1990; 11: 134138.
  • 30
    Ohmagari N,Hanna H,Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005; 104: 205212.
  • 31
    Wang WS,Liu CP,Lee CM,Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004; 37: 359365.
  • 32
    Spanik S,Krupova I,Trupl J, et al. Bacteremia due to multiresistant Gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother. 1999; 5: 180184.
  • 33
    Harris A,Torres-Viera C,Venkataraman L,DeGirolami P,Samore M,Carmei Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999; 28: 11281133.
  • 34
    Elting LS,Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore). 1990; 69: 296306.
  • 35
    Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia [review]. J Hosp Infect. 1995; 30( suppl): 453464.
  • 36
    Morrison AJ,Hoffmann KK,Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol. 1986; 24: 5255.
  • 37
    Vartivarian SE,Papadakis K,Anaissie EJ. Outcome of Stenotrophomonas maltophilia infections in cancer patients. In: Program and Abstracts of the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract J-92), September 28-October 1, 1997, Toronto, Ontario, Canada.
  • 38
    Tsiodras S,Pittet D,Carmeli Y, et al. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis. 2000; 32: 651656.
  • 39
    Giamarellos-Bourboulis EJ,Karnesis L,Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 2002; 44: 259263.
  • 40
    Garcia Sanchez JE,Vazquez Lopez ML,Blazquez AM, et al. Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports. J Chemother. 1997; 9: 238240.